ETX101, an experimental one-time gene therapy for Dravet syndrome, has been granted breakthrough therapy designation by the U.S. Food and Drug Administration (FDA). The FDA grants this designation to investigational treatments for serious conditions that, based on early evidence, may offer a meaningful improvement over existing options. The designation…
News
ETX101, an investigational one-time gene therapy being developed by Encoded Therapeutics for children with Dravet syndrome, has shown a favorable safety profile and early signs of benefit in an ongoing clinical program. Called the POLARIS program, the clinical effort includes three Phase 1/2 trials of ETX101: ENDEAVOR (NCT05419492)…
Stoke Therapeutics plans to meet with the U.S. Food and Drug Administration (FDA) before the end of this year to review four years of safety and efficacy data on its experimental therapy zorevunersen for Dravet syndrome, and to discuss faster ways to make the treatment available to patients…
The U.S. Food and Drug Administration (FDA) has granted ETX101, an experimental gene therapy for Dravet syndrome, its regenerative medicine advanced therapy (RMAT) designation. According to developer Encoded Therapeutics, the RMAT status was awarded following positive clinical trial data. The regulatory designation is given to certain types of…
Zorevunersen continues to show durable reductions in seizure frequency — alongside gains in cognition, behavior, and day-to-day functioning — in children and adolescents followed for up to three years. The investigational therapy targets the genetic cause of Dravet syndrome. The findings come from two long-term extension studies that followed…
A Phase 3 clinical trial testing the therapy candidate zorevunersen for Dravet syndrome is now recruiting children who still experience seizures despite being on stable treatment with antiseizure medications. The study, dubbed EMPEROR (NCT06872125), is open to pediatric patients ages 2 to 17. Enrollment is ongoing at…
Daily treatment with Fycompa (perampanel), on top of standard medications, was safe and reduced seizure frequency for children with Dravet syndrome whose seizures had not been previously controlled with other therapies, according to an observational study in China. Fycompa’s benefits were observed in children of all ages, including…
June is Dravet Syndrome Awareness Month in the U.S., and the Dravet Syndrome Foundation is spearheading efforts to raise funds and spread the word about this rare type of epilepsy. “By raising awareness of Dravet syndrome, our community can increase knowledge in the general public, improve early diagnosis,…
Praxis Precision Medicines is gearing up to launch a clinical trial of its experimental anti-seizure therapy relutrigine in people with Dravet syndrome and other disorders that cause seizures in childhood, collectively known as developmental and epileptic encephalopathies (DEEs). According to a corporate presentation, the study, dubbed EMERALD,…
Long-term use of the approved Dravet syndrome therapy Fintepla (fenfluramine) safely and consistently reduces seizure frequency in children and young adults with the genetic condition, according to the final analysis of an open-label extension of a Phase 3 clinical trial. Dubbed ZX008-1503 (NCT02823145), the international long-term study tracked…
Recent Posts
- FDA grants breakthrough status to new gene therapy for Dravet syndrome
- First look at ETX101 suggests early benefits for children with Dravet
- Grief comes in waves and reminds me of the start of a long journey
- Stoke readies to meet with FDA on 4 years of zorevunersen study data
- Continuing family traditions helps keep my daughter’s memory alive
- FDA awards RMAT designation to Dravet syndrome gene therapy
- A return to homeschooling reminds me how high my daughter soared
- COULD IMPROVED SEIZURE CONTROL HELP YOUR LOVED ONE DO MORE OF WHAT THEY LOVE?
- Zorevunersen shows long-lasting seizure control in Dravet patients
- A hospital visit brings back memories of a helping community